Merck Donates a Half a Million Masks to Support COVID-19 Emergency Response in New York City
March 22 2020 - 11:52AM
Business Wire
In response to the calls for personal protective equipment for
healthcare workers and other front-line responders battling the
COVID-19 pandemic, Merck & Co., Inc. (NYSE:MRK), known as MSD
outside the U.S. and Canada, today announced it has provided a half
a million (500,000) personal protective masks to New York City for
use as part of urgent efforts to address the outbreak in New York.
These masks were delivered this morning to New York City Emergency
Management. As of Saturday, March 21, 2020, New York State had
confirmed more than 10,000 novel coronavirus cases.
“COVID-19 is a generational challenge to the global community,”
said Kenneth C. Frazier, chairman and chief executive officer,
Merck. “At Merck, we embrace our fundamental responsibility to
provide our essential medicines and vaccines to patients who need
them, especially in times of crisis, and to do our part to support
healthcare providers and their communities. We are enormously
grateful for the front-line healthcare personnel who are helping
the thousands of patients now affected by COVID-19.”
In response to the COVID-19 pandemic, Merck remains focused on
protecting the safety of its employees and their families, assuring
that our supply of medicines and vaccines reach our patients,
contributing our scientific expertise to the development of
antiviral approaches, and supporting our healthcare providers and
the communities in which they serve.
About Merck For more than 125 years, Merck, known as MSD
outside of the United States and Canada, has been inventing for
life, bringing forward medicines and vaccines for many of the
world’s most challenging diseases in pursuit of our mission to save
and improve lives. We demonstrate our commitment to patients and
population health by increasing access to health care through
far-reaching policies, programs and partnerships. Today, Merck
continues to be at the forefront of research to prevent and treat
diseases that threaten people and animals – including cancer,
infectious diseases such as HIV and Ebola, and emerging animal
diseases – as we aspire to be the premier research-intensive
biopharmaceutical company in the world. For more information, visit
www.merck.com and connect with us on Twitter, Facebook, Instagram,
YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA This news release of Merck & Co.,
Inc., Kenilworth, N.J., USA (the “company”) includes
“forward-looking statements” within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. These statements are based upon the current beliefs and
expectations of the company’s management and are subject to
significant risks and uncertainties. If underlying assumptions
prove inaccurate or risks or uncertainties materialize, actual
results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of the recent global outbreak of novel coronavirus
disease (COVID-19); the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by
competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing
difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of
the company’s patents and other protections for innovative
products; and the exposure to litigation, including patent
litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2019
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200322005018/en/
Media: Patrick Ryan (201) 452-2409
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024